Loading
This study tests TROP-2-directed treatment; the registry reports that it is active not recruiting.
The registry lists NCT05922930 as active not recruiting, last updated 2026-09-25. Enrolment is 51 planned participants, an estimate. Interventions: TROP2-CAR-NK, Cyclophosphamide, Fludarabine. Primary measures include Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0. No results are posted in the registry; this does not exclude separate publications.
Shares TROP2, Pancreatic ductal adenocarcinoma.
Shares TROP2, Ovarian cancer.
Shares TROP2, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/